Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florbetaben F18 - Piramal

Next Previous
Drug Profile

Florbetaben F18 - Piramal

Alternative Names: 18F-AV 1; 18F-AV1/ZK; [18F] florbetaben; AV-1; AV-1/ZK; BAY 94-9172; Florbetaben 18F; florbetaben18F; NeuraCeq; Neuraceq; UNII-TLA7312TOI; ZK 6013443

Latest Information Update: 19 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avid Radiopharmaceuticals
  • Developer Avid Radiopharmaceuticals; Bayer HealthCare Pharmaceuticals; Ci-Co Healthcare; FONDAZIONE TOSCANA GABRIELE MONASTERIO; Isologic Innovative Radiopharmaceuticals; PET Pharm Biotech; Piramal Enterprises; Sinotau Pharmaceuticals
  • Class Aniline compounds; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase III Amyloidosis
  • Phase II Cardiovascular disorders
  • Discontinued Mild cognitive impairment

Most Recent Events

  • 12 Mar 2025 Fundacion Clinic per a la Recerca Biomédica withdraws phase II trial for Cognition-disorders (Prevention) presumably, prior to enrollment as the sponsor cannot provide the study treatment (NCT03057938)
  • 31 Jan 2025 Life Molecular Imaging plans a phase I trial for Amyloidosis (Diagnosis), in April 2025 (NCT06790394)
  • 21 Jan 2025 Florbetaben F18 receives Fast track status from the US FDA for Amyloidosis (Diagnosis)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top